Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo

• US 10,046,066 B2
• Filed: 09/25/2014
• Issued: 08/14/2018
• Est. Priority Date: 09/25/2013
• Status: Active Grant

• Current Assignee: enGene, Inc.
• Original Assignee: enGene, Inc.
• Inventors: Gao, Jun, Hsu, Eric, Cheung, Anthony
• Primary Examiner(s): Burkhart, Michael
• Application Number:
  US15/025,218
• Publication Number:
  US 20160235863A1
• Time in Patent Office: 1,419 Days
• Field of Search: None
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: C08B 37/003 Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• CPC Class Codes: C12N 15/88 using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

Claims

1. A chitosan-derivative nanoparticle comprising chitosan functionalized with arginine (Arg) and a hydrophilic polyol (HP) of Formula VII:

2. The chitosan-derivative nanoparticle of claim 1, wherein the hydrophilic polyol has a carboxyl group.

3. The chitosan-derivative nanoparticle of claim 2, wherein the hydrophilic polyol is threonic acid.

4. The chitosan-derivative nanoparticle of claim 1, wherein the hydrophilic polyol is a saccharide selected from the group consisting of glyceraldehyde, threose, erythrose, ribose, arabinose, xylose, lyxose, allose, glucose, altrose, mannose, gulose, idose, galactose, and talose.

5. The chitosan-derivative nanoparticle of claim 1, wherein the hydrophilic polyol is selected from the group consisting of 2,3-dihydroxylpropanoic acid;

2,3,4,5,6,7-hexahydroxylheptanal;

2,3,4,5,6-pentahydroxylhexanal;

2,3,4,5-tetrahydroxylhexanal; and

2,3-dihydroxylpropanal.

6. The chitosan-derivative nanoparticle of claim 4, wherein the hydrophilic polyol is glucose.

7. The chitosan-derivative nanoparticle of claim 1, wherein the nanoparticle has an Arg final functionalization degree:

HP final functionalization degree ratio of between about 1;

1 to about 10;

1.

8. The chitosan-derivative nanoparticle of claim 7, wherein the Arg final functionalization degree:

HP final functionalization degree ratio is between about 3;

1 to about 7;

1.

9. The chitosan-derivative nanoparticle of claim 8, wherein the Arg final functionalization degree:

HP final functionalization degree ratio is about 5;

1.

10. A composition comprising the nanoparticle according to any one of claims 1-6 and 7-9, wherein said chitosan is complexed with a nucleic acid to form a dually derivatized (DD) chitosan nucleic acid polyplex.

11. The composition according to claim 10, wherein said nucleic acid is DNA or RNA.

12. The composition according to claim 11, wherein the amine to phosphate ratio of said DD-chitosan nucleic acid polyplex is between 2 to 100.

13. The composition according to claim 12, wherein the amine to phosphate ratio of said DD-chitosan nucleic acid polyplex is between 2 to 50.

14. The composition according to claim 13, wherein the amine to phosphate ratio of said DD-chitosan nucleic acid polyplex is between 2 to 30.

15. The composition according to claim 14, wherein the amine to phosphate ratio of said DD-chitosan nucleic acid polyplex is between 2 to 15.

16. A method of delivering a nucleic acid molecule to a cell comprising contacting said cell with a composition according to claim 11.

17. The method of claim 16, wherein said cell is in vivo.

18. The composition according to claim 10, wherein said nucleic acid is an artificial nucleic acid.

19. The composition according to claim 18, wherein said artificial nucleic acid is selected from the group consisting of locked nucleic acid (LNA), glycol nucleic acid (GNA), and threose nucleic acid (TNA).

20. The composition according to claim 10, wherein said nucleic acid is a therapeutic nucleic acid.

21. The composition according to claim 19, wherein said therapeutic nucleic acid is a therapeutic RNA.

22. The composition according to claim 20, wherein said therapeutic RNA is an antisense RNA, siRNA, short hairpin RNA, mRNA, micro RNA, or enzymatic RNA.

23. The composition according to claim 10, wherein said polyplexes comprise chitosan molecules having an average molecular weight of less than 65 kDa before functionalization.

24. The composition according to claim 23, wherein said polyplexes comprise chitosan molecules having an average molecular weight of less than 30 kDa before functionalization.

25. The composition according to claim 10, wherein said composition has a pH between 4.0-7.0.

26. The composition according to claim 25, wherein said composition has a pH between 4.5-6.5.

27. The composition according to claim 10, wherein said DD-chitosan nucleic acid polyplex has an average polydispersity index (PDI) less than 0.4.

28. The composition according to claim 27, wherein said DD-chitosan nucleic acid polyplex has an average polydispersity index (PDI) less than 0.25.

29. The composition according to claim 10, wherein said chitosan-nucleic acid polyplexes comprise chitosan molecules having an average molecular weight of less than 50 kDa before functionalization, on average less than 310 glucosamine monomer units, an N/P ratio of 2 to 20, an average hydrodynamic diameter of less than 500 nm, an average hydrodynamic diameter of less than 500 nm, an average zeta potential of at least 0 mV at an acidic pH, a polydispersity index (PDI) of less than 0.5, and a nucleic acid concentration greater than 0.5 mg/ml, wherein said chitosan-nucleic acid polyplexes are substantially free of precipitated polyplex and are size stable in that they increase in average diameter by less than 100% at room temperature for at least 6 hours, at least 12 hours, at least 24 hours, or at least 48 hours.

30. The composition according to claim 10, wherein said chitosan-nucleic acid polyplexes comprise chitosan molecules having an average molecular weight of less than 65 kDa before functionalization, on average less than 400 glucosamine monomer units, an N/P ratio of 2 to 20, an average hydrodynamic diameter of less than 500 nm, an average zeta potential of +1 to +40 mV at an acidic pH, a polydispersity index (PDI) of less than 0.4, and a nucleic acid concentration greater than 0.5 mg/ml, wherein said chitosan-nucleic acid polyplexes are substantially free of precipitated polyplex and are size stable in that they increase in average diameter by less than 50% at room temperature for at least 6 hours, at least 12 hours, at least 24 hours, or at least 48 hours.

31. The composition according to claim 10, wherein said chitosan-nucleic acid polyplexes comprise chitosan molecules having an average molecular weight of less than 40 kDa before functionalization, on average less than 250 glucosamine monomer units, an N/P ratio of 2 to 20, an average hydrodynamic diameter of less than 500 nm, an average zeta potential of +1 to +30 mV at an acidic pH, a polydispersity index (PDI) of less than 0.3, and a nucleic acid concentration greater than 0.5 mg/ml, wherein said chitosan-nucleic acid polyplexes are substantially free of precipitated polyplex and are size stable in that they increase in average diameter by less than 50% at room temperature for at least 6 hours, at least 12 hours, at least 24 hours, or at least 48 hours.

32. The composition according to claim 10, wherein said chitosan-nucleic acid polyplexes comprise chitosan molecules having an average molecular weight of less than 30 kDa before functionalization, on average less than 190 glucosamine monomer units, an N/P ratio of 2 to 5, an average hydrodynamic diameter of less than 500 nm, an average zeta potential of +1 to +30 mV at an acidic pH, a polydispersity index (PDI) of less than 0.25, and a nucleic acid concentration greater than 0.5 mg/ml or 0.75 mg/ml, wherein said chitosan-nucleic acid polyplexes are substantially free of precipitated polyplex and are size stable in that they increase in average diameter by less than 25% at room temperature for at least 6 hours, at least 12 hours, at least 24 hours, or at least 48 hours.

33. The composition according to claim 10, wherein said chitosan-nucleic acid polyplexes comprise chitosan molecules having an average molecular weight of less than 15 kDa before functionalization, on average less than 95 glucosamine monomer units, an N/P ratio of 2 to 5, an average hydrodynamic diameter of less than 200 nm, an average zeta potential of +1 to +30 mV at an acidic pH, a polydispersity index (PDI) of less than 0.25, and a nucleic acid concentration greater than 1.0 mg/ml, wherein said chitosan-nucleic acid polyplexes are substantially free of precipitated polyplex and are size stable in that they increase in average diameter by less than 50% at room temperature for at least 6 hours, at least 12 hours, at least 24 hours, or at least 48 hours.